# Invesco CurrencyShares Canadian Dollar Trust: financial statements, quarterly

FXC · NYSE · CIK 1353612 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fxc.md) · [Financials](/companies/fxc/financials.md) · [Filings](/companies/fxc/filings.md) · [Insiders](/companies/fxc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fxc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [554](/filings/0000950170-24-122607.md) | [535 d](/filings/0000950170-25-027265.md) | [458](/filings/0000950170-25-067204.md) | [402](/filings/0000950170-25-105143.md) | [362](/filings/0001193125-25-270329.md) | [271 d](/filings/0001193125-26-083543.md) | [189](/filings/0001193125-26-209777.md) | [195](/filings/0001193125-26-338711.md) | [209](/filings/0001193125-25-270329.md) | [121 d](/filings/0001193125-26-083543.md) | [104](/filings/0001193125-26-209777.md) | [98.8](/filings/0001193125-26-338711.md) |
| Income tax | $k | [0.0 d](/filings/0000950170-23-060469.md) | [0.0 d](/filings/0000950170-24-019058.md) | [0.0](/filings/0000950170-24-054968.md) | [0.0 d](/filings/0000950170-24-092109.md) | [0.0 d](/filings/0000950170-24-122607.md) | [0.0 d](/filings/0000950170-25-027265.md) | [0.0](/filings/0000950170-25-067204.md) | [0.0 d](/filings/0000950170-25-105143.md) | [0.0 d](/filings/0001193125-25-270329.md) | [0.0 d](/filings/0001193125-26-083543.md) | [0.0](/filings/0001193125-26-209777.md) | [0.0 d](/filings/0001193125-26-338711.md) |
| Net income | $k | [472](/filings/0000950170-24-122607.md) | [459 d](/filings/0000950170-25-027265.md) | [393](/filings/0000950170-25-067204.md) | [343](/filings/0000950170-25-105143.md) | [300](/filings/0001193125-25-270329.md) | [209 d](/filings/0001193125-26-083543.md) | [123](/filings/0001193125-26-209777.md) | [110](/filings/0001193125-26-338711.md) | [116](/filings/0001193125-25-270329.md) | [38.6 d](/filings/0001193125-26-083543.md) | [23.5](/filings/0001193125-26-209777.md) | [22.4](/filings/0001193125-26-338711.md) |
| Diluted EPS | $ per share | [0.43](/filings/0000950170-24-122607.md) | not reported | [0.43](/filings/0000950170-25-067204.md) | [0.41](/filings/0000950170-25-105143.md) | [0.35](/filings/0001193125-25-270329.md) | not reported | [0.12](/filings/0001193125-26-209777.md) | [0.09](/filings/0001193125-26-338711.md) | [0.09](/filings/0001193125-25-270329.md) | not reported | [0.02](/filings/0001193125-26-209777.md) | [0.02](/filings/0001193125-26-338711.md) |
| Basic EPS | $ per share | [0.43](/filings/0000950170-24-122607.md) | not reported | [0.43](/filings/0000950170-25-067204.md) | [0.41](/filings/0000950170-25-105143.md) | [0.35](/filings/0001193125-25-270329.md) | not reported | [0.12](/filings/0001193125-26-209777.md) | [0.09](/filings/0001193125-26-338711.md) | [0.09](/filings/0001193125-25-270329.md) | not reported | [0.02](/filings/0001193125-26-209777.md) | [0.02](/filings/0001193125-26-338711.md) |

- Revenue: us-gaap:Revenues
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [75.9](/filings/0000950170-23-060469.md) | [77.8](/filings/0000950170-25-027265.md) | [57.8](/filings/0000950170-24-054968.md) | [57.1](/filings/0000950170-24-092109.md) | [61.5](/filings/0000950170-24-122607.md) | [61.2](/filings/0001193125-26-083543.md) | [67.9](/filings/0000950170-25-067204.md) | [93.1](/filings/0000950170-25-105143.md) | [91.3](/filings/0001193125-25-270329.md) | [74.9](/filings/0001193125-26-338711.md) | [84.0](/filings/0001193125-26-209777.md) | [75.8](/filings/0001193125-26-338711.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [76.1](/filings/0000950170-23-060469.md) | [78.0](/filings/0000950170-25-027265.md) | [57.9](/filings/0000950170-24-054968.md) | [57.3](/filings/0000950170-24-092109.md) | [61.6](/filings/0000950170-24-122607.md) | [61.2](/filings/0001193125-26-083543.md) | [68.0](/filings/0000950170-25-067204.md) | [93.2](/filings/0000950170-25-105143.md) | [91.4](/filings/0001193125-25-270329.md) | [74.9](/filings/0001193125-26-338711.md) | [84.1](/filings/0001193125-26-209777.md) | [75.8](/filings/0001193125-26-338711.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total liabilities | $m | [0.0](/filings/0000950170-23-060469.md) | [0.0](/filings/0000950170-25-027265.md) | [0.0](/filings/0000950170-24-054968.md) | [0.0](/filings/0000950170-24-092109.md) | [0.0](/filings/0000950170-24-122607.md) | [0.0](/filings/0001193125-26-083543.md) | [0.0](/filings/0000950170-25-067204.md) | [0.0](/filings/0000950170-25-105143.md) | [0.0](/filings/0001193125-25-270329.md) | [0.1](/filings/0001193125-26-338711.md) | [0.0](/filings/0001193125-26-209777.md) | [0.0](/filings/0001193125-26-338711.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: not reported
- Total assets: us-gaap:Assets
- Current liabilities: not reported
- Total liabilities: us-gaap:Liabilities

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [470 d](/filings/0000950170-24-122607.md) | [457 d](/filings/0000950170-25-027265.md) | [427](/filings/0000950170-25-067204.md) | [363 d](/filings/0000950170-25-105143.md) | [311 d](/filings/0001193125-25-270329.md) | [245 d](/filings/0001193125-26-083543.md) | [143](/filings/0001193125-26-209777.md) | [107 d](/filings/0001193125-26-338711.md) | [122 d](/filings/0001193125-25-270329.md) | [63.5 d](/filings/0001193125-26-083543.md) | [22.9](/filings/0001193125-26-209777.md) | [23.7 d](/filings/0001193125-26-338711.md) |
| Dividends paid | $k | [468](/filings/0000950170-24-122607.md) | [420 d](/filings/0000950170-25-027265.md) | [416](/filings/0000950170-25-067204.md) | [353](/filings/0000950170-25-105143.md) | [311](/filings/0001193125-25-270329.md) | [246 d](/filings/0001193125-26-083543.md) | [143](/filings/0001193125-26-209777.md) | [111](/filings/0001193125-26-338711.md) | [122](/filings/0001193125-25-270329.md) | [60.9 d](/filings/0001193125-26-083543.md) | [23.1](/filings/0001193125-26-209777.md) | [23.4](/filings/0001193125-26-338711.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [1,379](/filings/0000950170-23-060469.md) | [1,359](/filings/0000950170-24-054968.md) | [1,340](/filings/0000950170-24-092109.md) | [1,109](/filings/0000950170-24-122607.md) | [903](/filings/0000950170-25-067204.md) | [827](/filings/0000950170-25-105143.md) | [861](/filings/0001193125-25-270329.md) | [988](/filings/0001193125-26-209777.md) | [1,203](/filings/0001193125-26-338711.md) | [1,308](/filings/0001193125-25-270329.md) | [1,147](/filings/0001193125-26-209777.md) | [1,075](/filings/0001193125-26-338711.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,100,000 at 2026-06-30, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-338711.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.